Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Theravance Biopharma (TBPH) Stock Price
Press coverage about Theravance Biopharma (NASDAQ:TBPH) has been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Theravance Biopharma earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.5834141850197 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of Theravance Biopharma (TBPH) opened at $26.95 on Tuesday. Theravance Biopharma has a 1-year low of $23.15 and a 1-year high of $43.44. The company has a quick ratio of 7.21, a current ratio of 7.53 and a debt-to-equity ratio of 1.21.
Several brokerages have recently issued reports on TBPH. Cantor Fitzgerald reissued a “buy” rating and set a $55.00 price target on shares of Theravance Biopharma in a report on Tuesday, November 7th. ValuEngine downgraded shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Tuesday, November 14th. Zacks Investment Research raised shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a report on Tuesday, September 5th. Robert W. Baird reissued a “sell” rating and set a $22.00 price target on shares of Theravance Biopharma in a report on Wednesday, November 1st. Finally, Evercore ISI began coverage on shares of Theravance Biopharma in a report on Wednesday, August 16th. They set an “outperform” rating and a $45.00 price target for the company. Three analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. Theravance Biopharma presently has a consensus rating of “Hold” and a consensus price target of $41.86.
TRADEMARK VIOLATION WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-theravance-biopharma-tbph-stock-price/1758532.html.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Ratings for Theravance Biopharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.